# Dexcom: how the business works

> For learning only. Cityfort is not a registered investment adviser or broker-dealer and does not recommend buying or selling any security. Prices shown are dated and may be out of date.

DexCom, Inc. · NASDAQ: DXCM · Sector: Health Care

Updated for Q3 FY2026 · checked Nov 20, 2026

This is the plain-text version of https://cityfort.co/stocks/dexcom. Source ids in [brackets] refer to the list at the end. Credit: "Cityfort, Dexcom: how the business works", with the page URL.

## The 30-second summary

Dexcom makes continuous glucose monitors, wearable sensors that read blood sugar all day, with revenue of $4.66 billion and net income of $836.3 million in FY2025. Distributors brought in 84.9% of FY2025 revenue, and three of them each accounted for 35% to 55%. Dexcom's only debt at Sep 30, 2026 was $1.25 billion of convertible notes due 2028, against $1.82 billion of cash and short-term investments.

## 5 points

- **What it sells:** Dexcom sells continuous glucose monitors, such as the prescription G7 and the Stelo biosensor sold without a prescription, with FY2025 revenue of $4.66 billion. [S4]
- **Who pays it:** Distributors and wholesalers brought in 84.9% of Dexcom's FY2025 revenue and its direct sales 15.1%; Medicare, Medicaid and insurers pay much of the cost in the end. [S4]
- **What it keeps from $100:** Of every $100 that came in during FY2025, Dexcom kept $17.3 as net income, which included $78.1 million of gains on equity investments; operating income was $19.6 per $100 of revenue. [S4]
- **Where the operating profit comes from:** Dexcom reports one segment, so its operating profit comes from sensors and systems: gross profit was $2.80 billion in FY2025, before $599.1 million of research and $1.29 billion of selling and administrative costs. [S4]
- **The one thing to watch:** International revenue grew 5% as reported in Q3 FY2026, after 26% in Q1 FY2026, while US revenue grew 14% in Q3 FY2026. [S18, S16]

## What does Dexcom sell?

Dexcom makes continuous glucose monitors (CGMs): a small sensor worn on the body that reads blood sugar all day. Readings go to a phone, a receiver or a partner's insulin pump every five minutes, so users rarely need finger-prick tests.

- **Dexcom G7 and G7 15 Day:** Prescription CGMs for people with Type 1 or Type 2 diabetes. The G7 sensor is thrown away after 10 days; the G7 15 Day sensor, launched in the US in late 2025, lasts 15.5 days. [S4, S19]
- **Stelo:** A glucose biosensor sold without a prescription, launched in August 2024 for adults with prediabetes or Type 2 diabetes who do not use insulin. In June 2026 the FDA cleared it for children aged 2 and older who do not use insulin. [S4, S1]
- **Dexcom One and Dexcom ONE+:** Other Dexcom CGM systems, sold mainly outside the US. [S4]
- **Software:** Apps and tools built on the sensor data, such as Dexcom Smart Basal, cleared by the FDA in Q4 FY2025 to help clinicians set long-acting insulin doses. [S19, S15]

## Who pays Dexcom?

- **Distributors and wholesalers (84.9% of revenue):** Companies that buy the sensors and supply pharmacies, patients and health systems. They brought in $3.96 billion of FY2025 revenue. [S4]
- **Direct sales (15.1% of revenue):** Sales Dexcom makes itself, mainly outside the US: $703.0 million in FY2025. [S4]
- **Medicare, Medicaid and insurers (who pay in the end):** In the US the G7 is covered by Medicare, by Medicaid in most states and by commercial insurers for eligible people with diabetes. Rebates to pharmacy benefit managers and payers reduce the revenue Dexcom records. [S4]
- **Customer concentration:** largest customer 55.0% of revenue. Three customers, named only as A, B and C in the FY2025 10-K, each brought in 10% or more of FY2025 revenue: Customer A 55%, Customer B 35% and Customer C 46%. They add up to more than 100% because the company counts each customer's sales net of its own rebates only. Distributor and direct shares are a Cityfort calculation from the FY2025 10-K. [S4]

## Where the money went (FY2025)

1. Distributors, pharmacies and some patients paid Dexcom $4.66 billion for sensors and systems in FY2025.
2. Making the products took $1.86 billion, leaving $2.80 billion of gross profit.
3. Research cost $599.1 million and selling, general and administrative costs $1.29 billion.
4. Other income, net, including $78.1 million of equity investment gains, added $176.6 million.
5. After $252.1 million of income tax, $836.3 million was left as net income.

Sources: S4.

## Key numbers by year (US$ million)

Financials: consolidated, US$ million. Fiscal years are the company's own: Fiscal year ends Dec 31. — = not shown on the page.

| Year | Revenue | EBITDA | EBITDA margin | Net profit | Net margin | EPS (US$ per share, diluted) | Operating cash flow | Capital spending | Free cash flow | Sources |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| FY2021 (restated) | 2,448.5 | 367.8 | 15.0% | 216.9 | 8.9% | 0.53 | 442.5 | 389.2 | 53.3 | S14, S12 |
| FY2022 | 2,909.8 | 547.1 | 18.8% | 341.2 | 11.7% | 0.82 | 669.5 | 364.8 | 304.7 | S13 |
| FY2023 | 3,622.3 | 783.7 | 21.6% | 541.5 | 14.9% | 1.3 | 748.5 | 236.6 | 511.9 | S12 |
| FY2024 | 4,033 | 817.7 | 20.3% | 576.2 | 14.3% | 1.42 | 989.5 | 358.8 | 630.7 | S8 |
| FY2025 | 4,662 | 1,163.6 | 25.0% | 836.3 | 17.9% | 2.09 | 1,440.7 | 363.5 | 1,077.2 | S4 |

- EBITDA here = operating income plus depreciation and amortization (from the cash flow statement).
- Net profit is the share belonging to the company's owners.

## Balance sheet (as of Sep 30, 2026, US$ million)

Cash and short-term investments of $1.82 billion were larger than the $1.24 billion of convertible notes at Sep 30, 2026. [S1, S16, S4]

| Item | Value |
| --- | --- |
| Total debt | 1,243.7 |
| Cash and investments | 1,817.9 |
| Net debt (debt minus cash) | −574.2 |
| Net worth (shareholders' money) | 2,535.4 |
| Debt to equity (times) | 0.49 |

- Net cash of $574.2 million is a Cityfort calculation from the Q3 FY2026 10-Q. It is cash of $961.4 million plus $856.5 million of short-term marketable securities, minus the $1,243.7 million carrying value of the notes.
- The only debt is $1.25 billion of 0.375% convertible notes due May 15, 2028. Holders can swap them for shares at $162.41 each; Dexcom may settle in cash, shares or both.
- A $200 million revolving credit line signed in September 2026 and maturing in September 2031 was undrawn at Sep 30, 2026.
- Dexcom repaid $1.21 billion of 0.25% convertible notes in cash when they matured in November 2025.

## Who owns Dexcom? (as of Apr 1, 2026)

Each share has one vote and no holder controls Dexcom. Directors and executive officers (16 people) held 1,062,400 shares; their 0.3% is a Cityfort calculation from the 2026 proxy statement. [S15, S1]

- Officers and directors (as a group), shares: 0.3%

| Class | Shares (millions) | Votes per share | % of shares | % of votes | Traded | Sources |
| --- | --- | --- | --- | --- | --- | --- |
| Common stock (372,950,922 shares outstanding at Oct 22, 2026 (Q3 FY2026 10-Q cover); 385,872,977 at the proxy's Apr 1, 2026 record date.) | 372.95 | 1 | — | — | Yes | S1, S15 |

Holders of 5% or more (each row shows the date of its own filing):

| Holder | Shares | Votes | As of | Note | Sources |
| --- | --- | --- | --- | --- | --- |
| The Vanguard Group | 12.8% | — | Apr 1, 2026 | 49,455,578 shares, per a Schedule 13G/A filed Oct 30, 2025, quoted in the 2026 proxy. | S15 |
| BlackRock, Inc. | 8.4% | — | Apr 1, 2026 | 32,504,140 shares, per a Schedule 13G/A filed Apr 24, 2025, quoted in the 2026 proxy. | S15 |

## What could go wrong

### Competition from Abbott's Libre and others

The 10-K calls the market intensely competitive. Abbott, MiniMed, Roche and others sell glucose monitors, and Abbott has FDA clearance to link certain Libre sensors to insulin delivery systems. [S4]

What to watch: US and international revenue growth each quarter in the earnings release.

### FDA warning letter

The March 2025 letter describes manufacturing and quality-system non-conformities. The 10-K warns that failing to satisfy the FDA could lead to restrictions or product withdrawals. [S4]

What to watch: Any FDA close-out letter or new action mentioned in a 10-Q.

### Medicare competitive bidding and rebates

Medicare bidding for CGMs starts with contracting in 2027 and payment changes from Jan 1, 2028. The FY2025 10-K says CMS anticipates awarding 10 contracts for CGMs. Pharmacy rebates already lower the revenue Dexcom records. [S4]

What to watch: Contract awards in 2027 and any pricing effect the 10-K describes.

### Reliance on three large customers

Customers A, B and C brought in 55%, 35% and 46% of FY2025 revenue. The 10-K says a large drop or loss of these sales could have a material adverse effect. [S4]

What to watch: Customer shares in the FY2026 10-K.

### Lawsuits over the G7 and past statements

Securities and consumer class actions allege that Dexcom made misleading statements and that its devices did not perform as advertised. The 10-Q states no amounts. [S1]

What to watch: A ruling on the motion to dismiss in Prime v. Dexcom, the Ninth Circuit appeal in the 2024 securities case, and the consolidated complaint in In re: Dexcom CGM Litigation.

### Few factories

Most products come from Mesa and Penang, and the Ireland plant is still being built. The 10-K notes the earthquake risk at its California sites. [S4]

What to watch: Capital spending and the Ireland plant's start-up.

## What to watch

Next: Q4 FY2026 results, Date not announced yet.

- **Full-year revenue against the company's range:** On Oct 29, 2026 Dexcom said it expects FY2026 revenue of $5.20 billion to $5.25 billion. Revenue for the first nine months was $3.84 billion.
- **International growth:** International revenue growth, as reported, was 26% in Q1, 19% in Q2 and 5% in Q3 FY2026. US growth was 14% in Q3.
- **Medicare competitive bidding:** Contracting for CGMs starts in 2027 and payment changes from Jan 1, 2028. The FY2025 10-K says CMS anticipates awarding 10 contracts.
- **Lawsuits and the FDA letter:** A ruling on the motion to dismiss in Prime v. Dexcom, the Ninth Circuit appeal in the 2024 securities case, and the consolidated complaint in In re: Dexcom CGM Litigation, and any FDA close-out letter or new action reported in a 10-Q.

## Sources

- S1: Form 10-Q for Q3 FY2026. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1093557/000109355726000195/0001093557-26-000195-index.htm (published Oct 29, 2026)
- S2: Form 10-Q for Q2 FY2026. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1093557/000109355726000143/0001093557-26-000143-index.htm (published Jul 30, 2026)
- S3: Form 10-Q for Q1 FY2026. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1093557/000109355726000073/0001093557-26-000073-index.htm (published Apr 30, 2026)
- S4: Form 10-K for FY2025. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1093557/000109355726000027/0001093557-26-000027-index.htm (published Feb 12, 2026)
- S5: Form 10-Q for Q3 FY2025. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1093557/000109355725000280/0001093557-25-000280-index.htm (published Oct 30, 2025)
- S6: Form 10-Q for Q2 FY2025. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1093557/000109355725000243/0001093557-25-000243-index.htm (published Jul 30, 2025)
- S7: Form 10-Q for Q1 FY2025. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1093557/000109355725000113/0001093557-25-000113-index.htm (published May 1, 2025)
- S8: Form 10-K for FY2024. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1093557/000109355725000036/0001093557-25-000036-index.htm (published Feb 18, 2025)
- S9: Form 10-Q for Q3 FY2024. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1093557/000109355724000180/0001093557-24-000180-index.htm (published Oct 24, 2024)
- S10: Form 10-Q for Q2 FY2024. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1093557/000109355724000144/0001093557-24-000144-index.htm (published Jul 25, 2024)
- S11: Form 10-Q for Q1 FY2024. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1093557/000109355724000079/0001093557-24-000079-index.htm (published Apr 25, 2024)
- S12: Form 10-K for FY2023. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1093557/000109355724000021/0001093557-24-000021-index.htm (published Feb 8, 2024)
- S13: Form 10-K for FY2022. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/0001093557-23-000024-index.htm (published Feb 9, 2023)
- S14: Form 10-K for FY2021. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1093557/000109355722000014/0001093557-22-000014-index.htm (published Feb 14, 2022)
- S15: 2026 Proxy Statement (DEF 14A). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1093557/000109355726000061/dxcm-20260415.htm (published Apr 15, 2026)
- S16: Q3 FY2026 earnings release (Form 8-K, Exhibit 99.1). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1093557/000109355726000193/dxcm09302026-exhibit991.htm (published Oct 29, 2026)
- S17: Q2 FY2026 earnings release (Form 8-K, Exhibit 99.1). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1093557/000109355726000142/dxcm06302026-exhibit991.htm (published Jul 30, 2026)
- S18: Q1 FY2026 earnings release (Form 8-K, Exhibit 99.1). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1093557/000109355726000072/dxcm3312026-exhibit991.htm (published Apr 30, 2026)
- S19: Q4 FY2025 earnings release (Form 8-K, Exhibit 99.1). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1093557/000109355726000025/dxcm12312025-exhibit991.htm (published Feb 12, 2026)
